MEDILABO RFP
WELCOME TO MEDILABO RFP
The Advanced Way
OUR STORY
Save Lives with Proven Science
We’re an experienced and talented group of entrepreneurs and scientists with a groundbreaking idea that we hope will contribute towards a better human life. We repurpose the currently available safe medicine to prevent and treat Dementia in any forms and pride ourselves on our unparalleled, dedicated efforts.
At Medilabo RFP, we believe that the right understanding of science as well as collaborative partnership can lead the company towards a successful future, saving millions of lives in the very immediate future.
OUR INNOVATIVE APPROACH
The Possibilities Are Endless
At Medilabo RFP, we thrives to find a way to support healthy fulfilling life of people with neurodegenerative diseases. Mdilabo RFP's disruptive findings about rifampicin's multi target mechanisms will make it possible to deliver the best possible treatments to the patients around the world safely, effectively and quickly
Rifampicin
Rifampicin is a safe antibiotic that has been approved and used for over five decades worldwide.
Leprosy and Tuberculosis are the diseases that Rifampicin is indicated for, and it is known that the patients taking Rifampicin for a certain amount of time are less susceptible to Dementia.
At medilabo RFP, we found that Rifampicin inhibits the formation of Aβ and Tau oligomers, inhibits Tau Propagation, attenuates oxidative stress as a radical scavenger, and suppresses glial inflammation.
Our lead product, ML1808, a rifampicin-based nasal spray, provides a promising measure for preventing neurodegenerative Dementia.
"The secret of getting ahead is getting started"